Biotechnology Companies By Book Value Per Share Ratio

Book Value Per Share
Book Value Per ShareEfficiencyMarket RiskExp Return
1GMAB Genmab AS
502.6
(0.05)
 1.83 
(0.10)
2ADTX Aditxt Inc
486.96
(0.40)
 7.46 
(3.02)
3REGN Regeneron Pharmaceuticals
272.04
(0.27)
 1.96 
(0.53)
4SCPX Scorpius Holdings
239.49
(0.08)
 10.71 
(0.82)
5UTHR United Therapeutics
136.74
 0.00 
 1.86 
 0.00 
6BIIB Biogen Inc
112.28
(0.30)
 1.44 
(0.44)
7BNTX BioNTech SE
79.73
 0.02 
 2.93 
 0.06 
8GRAL GRAIL, LLC
77.93
 0.09 
 5.21 
 0.44 
9BNR Burning Rock Biotech
75.01
 0.21 
 7.42 
 1.53 
10ARGX argenx NV ADR
71.28
 0.17 
 1.69 
 0.28 
11VRTX Vertex Pharmaceuticals
60.65
(0.09)
 2.26 
(0.20)
12TNXP Tonix Pharmaceuticals Holding
57.61
 0.09 
 19.59 
 1.76 
13TOVX Theriva Biologics
53.89
 0.04 
 9.92 
 0.39 
14LGND Ligand Pharmaceuticals Incorporated
44.84
 0.04 
 3.13 
 0.11 
15GLPG Galapagos NV ADR
43.41
(0.17)
 2.44 
(0.41)
16MDGL Madrigal Pharmaceuticals
35.64
 0.11 
 5.00 
 0.55 
17TIL Instil Bio
34.72
(0.08)
 6.83 
(0.57)
18GLMD Galmed Pharmaceuticals
33.01
(0.15)
 4.41 
(0.67)
19MRNA Moderna
30.98
(0.15)
 4.49 
(0.66)
20KRYS Krystal Biotech
30.81
(0.11)
 2.85 
(0.31)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation. The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.